FENC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fennec Pharmaceuticals Inc (FENC) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is undervalued relative to its peers, has a unique FDA-approved product with significant growth potential, and is projected to achieve 55% annual revenue growth through 2027. Despite short-term technical weakness, the long-term growth outlook and analyst support make it a strong candidate for investment.
The technical indicators suggest a bearish short-term trend. The MACD is below 0 and negatively contracting, the RSI is neutral at 34.451, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels are at S1: 6.215 and R1: 7.903, with the stock currently trading near support. This indicates potential downside risk in the short term but does not negate the long-term potential.
Analysts have initiated coverage with Buy/Overweight ratings and price targets of $16-$18, highlighting the company's undervaluation and strong revenue growth potential.
Fennec's Pedmark is the only FDA-approved therapy in its category, addressing a validated market with no competition.
Revenue increased by 73.84% YoY in Q4 2025, showcasing robust growth.
Recent financial results missed EPS and revenue expectations.
Gross margin dropped by 4.76% YoY, indicating potential cost pressures.
Short-term technical indicators are bearish, suggesting potential near-term downside.
In Q4 2025, revenue increased by 73.84% YoY to $13.78 million, net income improved by 159.14% YoY to -$5.14 million, and EPS improved by 142.86% YoY to -$0.17. However, gross margin dropped to 87.2%, down 4.76% YoY. Full-year 2025 sales totaled $44.6 million, reflecting strong growth but with ongoing losses.
Analysts are bullish on Fennec Pharmaceuticals. B. Riley and Piper Sandler initiated coverage with Buy/Overweight ratings and price targets of $16 and $18, respectively. They highlight the company's undervaluation, strong revenue growth potential, and the unique market opportunity presented by Pedmark.
